Citations

Clear

4847 citation(s) found for "Tu, Eric".

Abstract PO2-12-01: Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors
Sella, Tal , Zheng, Yue , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Rosenberg, Shoshana M. , Tamimi, Rulla M. , Borges, Virginia F. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-12-01-PO2-12-01

10.1158/1538-7445.sabcs23-po2-12-01 Get It

Abstract Background: Young BC survivors are at risk for impaired QOL in part due to issues that are unique to their life stage. We sought to characterize trajectories of QOL in the 5 years following diagnosis among young BC survivors as well as evaluate patient and clinical characteristics associated with poorer or deteriorating QOL trajectories over time. Methods: Women diagnosed with stage I-III BC at age ≤40 enrolled in the Young Women’s BC Study, a prospective cohort in North America, who completed ≥2 study surveys through 5 years of post-diagnosis follow-up. QOL was evaluated with the Cancer Rehabilitation Evaluation System (CARES) physical, psychosocial, and sexual subscale scores. Demographic, treatment, and clinical characteristics were ascertained through surveys and chart review. Longitudinal trajectories for each CARES subscale were defined using group-based trajectory modeling; associations between patient/clinical characteristics and trajectory group membership were estimated for each subscale using multivariable multinomial logistic regression. Results: Among 900 women, median age at diagnosis was 36 (range: 17-40) 89% were white, 2% Black, and 4% Hispanic. At baseline, 73% were partnered, 61% parous and 49% perceived themselves as financially comfortable. Most had hormone-receptor positive (74%), HER2-negative (70%) BC, and most received chemotherapy (82%); 36% underwent mastectomy with radiation. Physical and psychosocial scores each clustered into 4 trajectories, with >75% of participants clustering in groups reflecting excellent or good QOL that was stable over time and few (6% for physical and 4% for psychosocial) clustering into groups that reflected poorer QOL at baseline that did not improve over time. Sexual health trajectories were more variable, clustering into 5 trajectories, with over half of participants clustered into groups reflecting good (35%) or excellent (20%) QOL that remained relatively stable over time, 22% clustered into a trajectory that was poor at baseline but moderately improved over follow-up, 13% in a group that reflected deteriorating from moderate-to-poor QOL and 11% in a group with poor QOL at baseline that did not improve over time. In multivariable regression analyses (Table), factors associated with clustering in a poorer trajectory (vs. clustering in an excellent trajectory), in multiple QOL domains included baseline financial discomfort (associated with poorer QOL across all 3 domains), mastectomy+radiation (vs. lumpectomy, associated with poorer QOL across all 3 domains); chemotherapy receipt (associated with poorer physical and sexual health trajectories); and baseline BMI >25 (vs. 18.5-24.9, associated with poorer physical and poorer/deteriorating sexual health trajectories). Conclusions: Young BC survivors follow distinct QOL trajectories in survivorship. While most will not experience substantial QOL impairment through the first 5 years following diagnosis, a substantial minority report persistently poor or deteriorating QOL. The association between more extensive local therapy and poorer physical/psychosocial/sexual health trajectories underscores the importance of communicating the potential for negative QOL outcomes when women are making surgical decisions. Additionally, the pervasive impact of financial wellbeing on multiple QOL domains supports the potential value of systematic screening for and addressing of financial distress to prevent or mitigate financial toxicity in survivorship Factors associated with clustering in poorer/deteriorating (vs. excellent) QOL trajectories *Reference trajectory=excellent QOL Citation Format: Tal Sella, Zheng Yue, Kathryn Ruddy, Shari Gelber, Rulla Tamimi, Jeffrey Peppercorn, Lidia Schapira, Virginia Borges, Steven Come, Eric Winer, Ann Partridge, Shoshana Rosenberg. Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-01.
Clinical Characteristics and Longitudinal Outcomes in Heterogeneous Emphysema in SPIROMICS
Hong, Angela , Newell, John D. , Valipour, Arschang , Ortega, Victor E. , Cooper, C.B., Hansel, Nadia N. , Paine, Robert , Woodruff, P., Hong, A., Eddy, Rachel L. , Goldin, Jonathan , Hoffman, Eric A. , Abtin, Fereidoun G. , Criner, Gerard J. , Reinhardt, Joseph M. , Barr, R. Graham , Ohar, Jill , Curtis, Jeffrey L. , Cooper, C.B. , Drummond, Michael , Han, MeiLan King , Labaki, Wassim W. , Martínez, Fernando J. , Wells, J. Michael , Tashkin, Donald P. , Barjaktarević, Igor

Mayo Clinic

D13. DETERMINANTS OF DISEASE PROGRESSION AND DECLINE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6905-A6905

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6905 Get It

Longitudinal Progression of CT Emphysema Subtypes Using Density-based and Hidden Markov Measure Field-based Thresholds: The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Wysoczanski, Artur , Bowler, R.P., Cooper, Christopher B. , Menchaca, Martha , Ortega, Victor E. , Paine, Robert , Woodruff, Prescott G. , Laine, Andrew F. , Angelini, Elsa D. , Hermann, E.A. , Dransfield, Mark T. , Han, MeiLan King , Hoffman, Eric A. , Krishnan, Jerry A , Menchaca, M.G., Ohar, Jill , Smith, Benjamin M. , Sun, Yuan‐Wan , Barr, R. Graham

Mayo Clinic

D15. MACHINE LEARNING AND LARGE COHORT STUDIES TO UNDERSTAND EXPOSURE-RELATED LUNG DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6928-A6928

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6928 Get It

Computer Assisted Quantitative Image Analysis as a Pathway to Identification of Combined Pulmonary Fibrosis and Emphysema (CPFE): Analysis of the SPIROMICS Cohort
HOESTEREY, DANIEL , Kim, G.H.J., Lee, Jungmin , Pourzand, Lila , Oh, Andrea , Bateman, Lori A. , Cooper, C.B., Hansel, Nadia N. , Kim, V., Ortega, Victor E. , Paine, Robert , Peters, Stephen P. , Wang, J.M., Woodruff, Prescott G. , Abtin, F., Tashkin, Donald P. , Hoffman, Eric A. , Barr, R. Graham , Bowler, Russell P. , Cooper, C.B. , Couper, David , Curtis, Jeffrey L. , Dransfield, Mark T. , Drummond, Michael , Han, MeiLan King , Kaner, Robert J. , Krishnan, Jerry A , Martínez, Fernando J. , Reinhardt, Joseph M. , Wells, J. Michael , Goldin, Jonathan , Abtin, Fereidoun G. , Barjaktarević, Igor

Mayo Clinic

C24. CLINICAL, BIOLOGIC, AND RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5118-A5118

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5118 Get It

Tracheobronchomalacia on Dynamic Expiratory View: Concordance Assessment in Interpretation
Matatko, M., Edell, Eric S. , Lim, Kaiser G. , Bartholmai, Brian J.

Mayo Clinic

B21. RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3077-A3077

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3077 Get It

Bronchoscopic Lung Volume Reduction: Machine Learning Mathematical Model for Target Lobe Selection
Hostetter, Logan , Brown, L. E. , Rajagopalan, S., Scrodin, M. Dulohery, Edell, E.S., Lester, Michael , Maldonado, Fabien , Lentz, Robert J. , Peikert, T., Brown, L., Rajagopalan, S., Edell, Eric S. , Bartholmai, Brian J. , Peikert, Tobias

Mayo Clinic

B21. RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3065-A3065

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3065 Get It

The Microbiome of Idiopathic Subglottic Stenosis in a Tertiary Hospital
Guiance, Irene Riestra , Edell, Eric S. , Ekbom, Dale C. , Kanj, Amjad , Wolff, M., Bayan, Semirra L. , Skalski, Joseph H.

Mayo Clinic

B76. CHRONIC AIRWAY DISEASES: ABOVE AND BEYOND | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4434-A4434

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4434 Get It

Severe Airflow Obstruction in Advanced Sarcoidosis With Dramatic Response to Prednisone Treatment
Hostetter, L., Olson, Eric J. , Ryu, Jay H.

Mayo Clinic

C72. CASE REPORTS IN RESPIRATORY STRUCTURE AND FUNCTION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6377-A6377

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6377 Get It

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242